ILMN - Earnings call transcript Q3 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to the Third Quarter 2019 Illumina Earnings Conference. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question and answer session. [Operator Instructions] As a reminder this conference call maybe recorded.

I would now like to introduce your host for today's conference, Ms. Relations. Investor Illumina Ross, Jacquie

Jacquie Ross

Good afternoon the earnings for to and quarter of welcome third our fiscal call everyone year XXXX.

today, close and During released we will commercial call we question-and-answer the which review the session. a financial activity, after after the commentary of offer market host the on our will results

found had at Relations Investor section our website not a the have the to you review release, in earnings illumina.com. If chance it can be of

and of Officer Samad, Participating brief review President and today and Officer. for will Chief Sam results. will deSouza, Francis, Executive Illumina Financial Francis update be Chief on our will Sam provide a financial the our state business

our is the will forward-looking Litigation XXXX. statements intent be recorded being and Reform audio the regarding archived our call financial of Investors portion activity call our in of Private today's results made during will the Securities Act is that This section commercial be all and It under protected website.

or uncertainties, information and Forward-looking statements forward-looking statements. available based current are no events discussed. upon or those statements subject differ and are All Illumina to actual from projected materially to results these update obligation risks assumes may

to understand files Commission, differ, that results uncertainties To we most risks recent that Illumina's with including XX-K. documents could actual refer and cause the better the and Securities Exchange you the Illumina to and XX-Q forms

call Francis. to turn over With that, will the now I

Francis deSouza

and Jackie, you, good Thank afternoon, everyone.

fourth $XXX systems XX% with with more which million consumable Illumina was included Sequencing arrays reported in licensing by million Total in up a Sequencing third in previously $XX largely anticipated associated driven than sequencing revenue. revenue solid than offsetting business, decline line the expectation. was agreement XX% quarter. a with quarter and revenue our in growth IVD more revenue

sequencing was consumable the third HiSeq. $XX consumable shipments our Exceeding of third dollar every history. which XXXX. million million reflected billion of first million the to for the sequencing quarter of were $XXX system quarter, NovaSeq. of million grew $X.X for revenue for time family company’s compared the $XXX in $XXX Year-over-year in consumable XX% Sequencing almost High‐Throughput excluding growth under just growth

more XX% quarter highlighting ongoing and of third grew the sequencing both sequentially than in volume. expansion consumables HiSeq from NovaSeq slightly conversion the the

NovaSeq basis to over become the highest pull-through and During per the HiSeq sequencing seen the was million again surpassed data. quarter, at most the on so generating x system annualized an platform level this once $X year. far we’ve NovaSeq

consumables, low-throughput trends and couple there noting. worth mid to Moving of are

seeing in Dx. strong we First, uptick NextSeq are

Shipments NextSeq Our just SBA year, regulated NextSeq. of and in XXXX. represented NextSeq so Dx shipments over approximately of XX% have of compared CE version our this IVD mark to XX% far

of larger MySeq We seeing including transition notably our clinical to by growing are NextSeq breadth a also number DX, oncology. and customers applications volume of driven

on larger are for all MySeq pull-through to accessibility the intensity of in NextSeq our larger trends, future and to and handful continue their platforms NextSeq transitioning highlighting volume in result lower DX, we NovaSeq to of the of high transitioning near-term. increasing but sequencing uptake These customers a or NextSeq positive some see sequencing Finally, customers growth the indicators broadening applications.

customers sequencing. of will greater and spend anticipate content larger we grow these volumes, time, size, consumable Over sample higher depth that with total

to as continues Prep our Nextera the prep adoption of Solutions, increase library sequencing XXX consumable with Library contributed kit. strength to XXXX the well under just of represent our Oncology XX% growth driven total TruSight revenue. to of Finally, a quarter our consumables compared by sequencing third Flex XX% of as

million XX% $XXX was of up from same revenue up systems, sequentially sequencing the and slightly ago. quarter a to Moving year

highest fact shipment so and for year represented second this quarter expected strongest we far NextSeq. the both was the in As ever the quarter of and NovaSeq

associated shipments UK historical the while quite consistent, the the at remains range NovaSeq lower of was multi-unit end Biobank. the ASPs with due ASP NextSeq to

NovaSeq for to NovaSeq launch total to opportunity a at move customers still into plenty its of started HiSeq we first who there have third. XXXX. of taking of fourth is roughly their their the as least orders in year included bringing XX% number customers conversions It’s HiSeq NovaSeq clear that

see new NovaSeq High-Throughput new going We third strong quarter. to customers continue adoption these to to or a to among quarter close Illumina the with of to shipments in

NextSeq very XXXX strong to has Moving shipments. NextSeq, been system a year for

portfolio increasing our In shipment its strongest by driven from the expect performance the fact, year-to-date DX, momentum ever year-to-date. impart NextSeq strongest we to NextSeq shipment have

Low-Throughput system were the shipments full again, up year-to-date see iSeq in Once XXXX. and growth DX year DX sequentially EMEA. strength version driven our with exceeding family, shipments Within we in MiSeq MiSeq, impart MiniSeq by already

sequential Overall, pleased and in installed revenue was the with more revenue, NextSeq development Gel associated very the basis for that quarter leading than and for up base in our the licensing business. the indicator we IVD growth NovaSeq of from of it’s year UK. XX% $XXX demand the growing ago our the a particularly with Sequencing XX% decline sequencing a services higher in a program for reflects up with promising and are on of services sequencing and other offsetting expansion and consumable completion million same

our partners of Illumina revenue expect licensing see access select to these a collaborate with leverage accelerate and Through tests in to and NGS-based to combination and patient QIAGEN technology see opportunity development oncology including adoption IVD TruSight ultimately clinical our clinical expect for through to and the oncology program, third can we others efforts IVD quarter. multiplier clear partnerships, improving effects in our to reach contributed growth outcomes. with further In testing we you Adaptive. patient

XXX I the oncology profiling month, module mean as Last US pre-market XXX, continues gene of share over currently tests the that available committed submitted RUO and IVD. into comprehensive to our remained to to and first progress moving to FDA standard-of-care TSO towards pleased accelerating In panel adoption we the genomic time, am NGS approval the time.

and revenue the in due for and of from the third $XXX other. Illumina XX% across reflecting headwind service and quarter third a revenue lower quarter, down a million was microarray be both DTC. to year-over-year, of systems, XXXX primarily Total sequentially continue Arrays consumables to

of to Consumer We for NGS comprehensive expanded Genomics last product starting week health an deliver extension announced a see sequencing-based offerings. data technology new leverages on that example, to of set are Plus conditions. Ancestry more called AncestryHealth into the

While remain directly time. we in opportunity services do and individuals this not information expect DTC for that through do to growth their return near-term, consumer in to we more genomics the genomic future the like be the we optimistic believe engaging over in will with

Before take updates. moments some organizational to I over few share to Sam, like I’d hand a the call to

senior joined our Planning. as biopharma, Corporate two of First, Development Vice global roles new strategies, Senior research I’d across tools month M&A. developments, leading experience like Strategic Illumina to and welcome Joydeep President and and product has developing who over Joydeep last partnerships, of leadership including licensing diagnostics Goswami, decades and

We our have leadership team. are him join to thrilled

be Illumina Chairman stepped like contribution Jay Flatley will as Chairman of him from look since and Chairman in has Executive tenure his share his forward as to Chair January for I’d Executive And down thank XXXX. that as continuing to Chairman. CEO to Executive he also of as July transitioning as Jay Illumina’s served Xst. We

quarterly call over to review financials. the hand Sam our I’ll that, Sam? of a With for

Sam Samad

Thanks Francis.

the XX% volumes. headwind particular in million As quarter driven the sequencing sequencing arrays discussed, Americas million partially growth XX% grew last grew growing XX to associated by by year was offset revenue same oncology sequencing versus year-over-year business $XXX third revenue growth quarter microarrays. approximately offset across and a decline with by X% the with X% in Geographically, strength in clinical

large-scale by of EMEA X% initiatives. was impart driven growth

again, investments infrastructure initial for of NovaSeqs from and genomes. healthy research Once the Specifically, Biobank, contribution to the effort part a countries, as clinical use. of region placed these markets from a emerging the their saw sequence into with XXX,XXX UK both handful

The was sequencing year-over-year, $X net driven reproductive growth region the offset revenue revenue stocking research but the was and quarter by customers. was XXXX, but China tariff down X% Greater down delivered third clinical strong from oncology, by this in of lower million consumable activity health for from allowing X%.

$XX driven of with by and both growth was the revenue million in from Japan another for quarter growth third research. up region APJ X% quarter impart of Finally XXXX, the clinical

Moving stocking for to XX% year XXXX. to product third of quarter consumables a sequencing or ago quarter tariff the million allowing XX% revenue, in from same the activity the grew $XXX

resulted and MiSeq range As Francis were by transitional that the impacted factors $XXX,XXX at some below consumables pull-through NextSeq the to of and in Mid-Throughput $XX,XXX noted, pull-through the Low range. $XXX,XXX our to low-end of low-end $XX,XXX

XX% $XX million of reflecting down from other DTC XX% lower same were up other from down consumables year quarter reflecting and service the was Array DTC also a demand. of ago $XXX XX% same volumes. a was service year Sequencing revenue Array lower million ago, revenue year-over-year. the and quarter

lab service and and category services, this reminder, licensing including associated fees NICT fees, field with warranty development As and a test revenues includes agreements. licensing revenue

is but was between warranty historically contributor revenues, and category services, below this quarter. XX% largest the Typically, XX% which field in of and this XX% represented

The largest agreement this contributor that than IVD of QIAGEN. quarter was more licensing $XX with revenue the million included second

Oncology compared was development a growth partially sequencing offset year-over-year. service Gel other revenue up to by was sequentially also and ago. and Sequencing both volumes lower year

XX% with but as third system of when from shipments of a revenue shipments. revenue Moving from systems, instrument of line more million $XXX record a XXXX sequencing to the quarter, Arrays array revenue quarter. DTC. the revenue NovaSeq typical X% higher we result in system the $X saw of was associated with a quarter third quarter grew of down XXXX, represented in system total significantly Combined, million,

results I I references Before share website. Illumina's supplementary can on subsequent to reconciliation that the includes net data to of review results the measures, and and in highlight all attributable these compensation. will release encourage the that non-GAAP per today's non-GAAP stock-based income shareholders. which GAAP to Please be note earnings found I refer continue, you to available our

IVD oncology other XXX revenue sequencing up in of sequentially favorable mix. year-over-year partially growth and year-over-year margin instrument offset gross ASPs. and consumable lower reported approximately XXX XX.X% driven Notably, with service points and was licensing basis by points and the basis by Non-GAAP development

expenses project quarter. operating up and third from $XX Non-GAAP quarter hiring, million to the from down XX.X% million XX.X%, lower therefore operating margin expected was spend shifted that and quarter program $XXX the due delayed Non-GAAP quarter. from than of last fourth to were were last reprioritization

Non-GAAP tax year discrete was benefits tax adjustments due and of the expected rate release prior than to XX.X% return of tax reserves. to related lower

$X.XX of marketable income linearity securities. was per DSO difference of from quarter XX losses income $X.XX Cash as quarter the with operations revenue the GAAP share a from $XXX net equity $XXX was the of million or in net For third flow from third quarter. million. million XX days, result was diluted increased unrealized share per being diluted non-GAAP or last $XXX and primary days XXXX,

at the in repurchased items the short-term quarter. we million $X.X cash $XX third approximately the in common other of capital million investments. equivalents leaving ended of cash, and under therefore quarter $XXX the plan third end impacting $XXX quarter, with of terms available in were In third stock approximately cash, expenditures the current million and billion quarter the We

to expect the from Moving quarter guidance to we revenue grow quarter XXXX. of about fourth X% fourth

a in quarter sequencing the expect from consumables year We same ago. high-teens the to grow

gross quarter. and We as a third reflecting percent sequential to with expenses margin points we revenue of expect increase compared lower quarter typical expenses a operating mix basis non-GAAP to on approximately non-GAAP revenue a XXX more the rates last as to approximately return basis, from to XXX projects and delayed reflecting catch-up be basis points

rate compared down to in We flat the interest lower our expect third be in other cash due fourth tax equivalents income XX.X% rates to reported the quarter. on the and quarter be to roughly sequentially our to

continue the of growth year, full expect to XXXX X%. approximately we revenue For

We sequencing revenue shift and in primarily service with XX% sequencing albeit between mix, consumables other. our business year-over-year approximately grow expect continue to some and to sequencing

NovaSeq expect up to shipments from flat slightly continue We to XXXX. be to

XX% which now of we Finally, down our approximately to expect prior down from XX%. be compares to arrays expectation XXXX,

margin P&L, Moving gross we XX.X% be to compared up the slightly to rest reported XXXX in the to the of non-GAAP XXXX. expect

revenue to the reported effect operating We average headcount percentage includes as in improve dilutive XXXX versus compared diluted to XX.X% expect and full-year of reflecting notes. count we activities. be our non-GAAP OpEx XXXX. This points approximately weighted And convertible approximately to flat a the expenses of expect prioritization XXXX basis share XXX

GAAP result, As share is per and $X.XX full year to expected be non-GAAP a $X.XX. expected earnings share per and $X.XX. be $X.XX to is earnings between between

Francis. call I’ll hand back the to that, With

Francis deSouza

Thanks, Sam.

the up I questions, provisional on Pacific will proposed our a of comment the CMA’s call we Biosciences. and Before acquisition finding quick make open to

reviewing CMA of with of this the our we believe ahead. While continue weeks are pro-competitive we acquisition in process We’ll the to is still and the in the customers the the in discussions genomics best document, and industry. that continue interest

appreciation growing the the with standard build to time. be integrated clinicians continues among momentum that XXXX, to Looking care will into of genomics over

growing the of that clinical genomics. of a partnerships and of accelerate seeing IVDs pipeline NGS expand will for reach are the We adoption

Whole-genome insured continue coverage U.S. some We panels favorable liquid to for with lives XX% for disease reimbursement in the in almost to Whole-exome including Germany’s high-risk oncology decisions biopsy. and see broader adoption all with continues European developments including grow for pregnancies. undiagnosed for NIPT plan And of see sequencing. for Coverage some seven continue having both NIPT testing reimburse we of positive alone in XXXX to reimbursement NIPT to

as the UK immunology, all UK’s to provide in XXXX. National to has single-cell has of as we potential into sequencing scaling insights research started Health oncology and methodologies The Biobank start such XXX,XXX both therapeutic samples Service neurology. us and the its And and such transcriptomics and in expect spatial areas advancements

our of is partners customers that world to where standard the menu into incorporated with innovate clinical improves lead Illumina outcomes. and and the will for impactful accelerate to of care genomics availability to a continue

to I’ll the to the invite now operator call up open questions.

Operator

first Our JPMorgan. Instructions] comes from [Operator Tycho question Peterson from

Your open. line is Please go ahead. now

Tycho Peterson

talk about captured you this how year quarter? of all Hey, us. POPSEQ UK thanks. then, Can from much think the UK what year? Biobank can actually on Francis, for about should and next fourth talk quarter think pacing how Biobank? we you And as we next you And expect in you

Francis deSouza

Tycho. Yes, sure,

as and deal of So both the as QX. as UK up know, Biobank, to starting in terms sequencing their signed ramp sequencing you systems the in QX well taking in started

next they through as work that few samples. to for quarters running the XXX,XXX the expect be We

as year. so, to for driver, expect as next be a well revenue that And QX revenue a driver we

revenue In XXXX terms XXXX that of to expect really revenue All of Us, we driver. be a driver, not

to discussions the next work they the So we They through continuing genomic in to IRB got and FDA expect the with of they service are ramp year. and through. the are the to up start them counseling They first working signed are in up. part

Sam Samad

Tycho though testing we that, centers the And that did I are size add, to for didn’t specifically, we it, will work the Biobank. we with instruments UK even for have some that QX placed performing

to QX were instruments the Some in NovaSeq some and work samples. doing on that start the placed consumables

Francis deSouza

Tycho, are shape start one do next to more ramp the at of the the initiative add with national year that to to expect and up just next course year I the so working of the if we Again in expect up beginning said, other that year then following and ramp that thing next what Sam over we to and ramping is we them we from of on the the on, expect play out NHS years.

Tycho Peterson

in Okay. underlying $XX about, dynamics had if on of to comp in this you you Or in alluded said, are you the talk China? stocking follow-up for quarter. just China, what and moving Sam Can one ask still last I then the a million $X and in could million kind was customers as quarter? you this out And net think

Francis deSouza

Yes, thanks, Tycho.

see So, quarter. this with regards decline to a China, we did

that you on in by that, seeing of actually clinical. we side just flat stocking strong for it’s our China essentially mentioned. we the you business, are seeing is, in very normalize clinical what growth But If are driven roughly the

We oncology testing, testing, strong disease are seeing in genetic testing. growth NIPT

believe down that’s Where fundamentally, the funding in down research of driven says we have in the that we’ve year-over-year. declined XX% on driven actually some of seen the business concerns is business part funding see We we by there. side some weakness research decline that’s is research that data in a and China and by macroeconomic of or the China

there seeing, stocking a But it’s normalization really, down. but being there. related clinical to two-part research with Not strong So, in being very much, are I that’s some story as we story is QX. mean, really the

Operator

next Souda comes Your Puneet question from Leerink. SVB

line Your is go open. Please ahead.

Puneet Souda

you of If just the that there? ask last clear. a Francis. sort sense the clarity? more I some Do any have quarter, hi, weakness could think was the you of around Yes, units, desktop wasn’t gave What in I driving

NextSeq bit of little market? is out a comments the seize to Could the in growth, It continuing what end. pull-through elaborate around but lower seems like that you fundamentally being is driving pointed couple the you DX on around

Francis deSouza

Yes, Puneet. thanks, Sure,

on fact were quarter, had the of of data we out. side we seeing desktop talked about are another we trends portfolio quarter the So, play last we’ve pull-through and the that seeing now lower and two

are play One customers trend systems. we we seeing out are is seeing migrates bigger buy and

in buy move So we seeing of end base, are we opting at customer are are to end at base, the NextSeq customers seeing on top of the NextSeq up some top the customers the some usage, to MiSeq terms NovaSeq. and customer

are existing from put because ramp platforms in but platforms bigger downward buy to have pull do signs up on utilization their the term customers good they transitions go these they some going their to is near pressure that tend through us systems. larger over on their General time. to the up So, bigger for systems, as expectations usage

are second The customers on really portfolio we you we the portfolio is actually play DX touched the and out XX% our – future a the MiSeq DX. shipments are clinical NextSeq of terms are from to seeing that has portion the that start of of in what XX% business grown That’s trend we seeing is terms as and that growth both NextSeq portfolio seeing overall the shipments purchase NextSeq NextSeq and of the NextSeq last year. in that sign of in this year portfolio, to our of good

in portfolio. NextSeq the DX good really growth So

some terms that’s and that indicator near-term of the the boxes. start DX downward Again, usage, as put positive validate transition in has but customers a in long-term pressure

the portfolio. of So out trends that are that two the we those play end in are seeing

Puneet Souda

central I bit to of back look on at bit of terms drove market NovaSeq And back that in Thanks. X elasticity and HiSeq a we XXXX through the bit you and drove little my then to launched XXXX. Okay. the you Then in launched Illumina. XXXX, go a saw follow-up demand a of When a that’s here throughout slowdown and the thesis XXXX growth going which XXXX broader. am is growth XXXX. in we strong

that of demand be as played now here, seem will elasticity in continue The growth. well XXXX here. two out drive consumables you into these But suggesting we to head very periods to major NovaSeq

but say to So you to XXXX the new demand understand of really an trying growth of here about instrument next that around anything I that, potential to I and to we is appreciate and hard should a elasticity am think which that’s catalyst absence for here is the how and beyond? key

Francis deSouza

may an interesting that that, the Sure, we that launched back I is, wanted new touched you when so, you customers about look there have saw up and launch is and to point an is we when which pick transition on touched you instrument, on and apparel before DX. a what we

of about of the up I’ll with again. what we bit when and pick saw the than a And again But DX. little we we drop go a that and played quarters couple the a a even that then years out there saw quarters pull-through, talk as that for customers migrate in you where later as was case, on launched and is further to couple a touched instrument, HiSeq few HiSeq bigger

side to for that’s the I the when were moving are just from portfolio about exact the the And migrating example up so, NextSeq to DX a so same of they customers phenomenon. MiSeq, instrument, bigger talked and desktop

of couple play In a cases, they that’s that, customers in the that – doesn’t out. that out our plays box. and that is so, they a And more we’ve will they buy quarters an the it they buy that, the some business learned a of how in box, what it’s Right, typically HiSeq. bigger when case have quarter example, from for it have expectation

you so, Separately, things that the sequencing to of of population elasticity and starting include fact about going to that the And we ramp drivers up. we that’s business efforts expect you seeing. touched the see on in are like, talked are the so for example, drivers the as forward some

for QX. at of Biobank UK ramped tail example, up So the end

All just start the QX. XXXX. in not going all in play to through of to XXXX. But Us talked going about out that's of beginning That’s We

wasn’t a in really winding in at XXXX. in the gap So it factor all but wasn’t we Similarly were at this it’s NHS, a down. to all, factor between fact XXXX caught Gel the out over year going play and

than yet And up. not that so, a and factor will this less And Gel had we next last the year. NHS year revenue year ramping be from

year And so, over expect those some year. to next of things that the we are be incremental this

Operator

Cowen. question next from ahead. from go comes Schenkel Your Doug Please

Your open. line is

Doug Schenkel

everybody. Good Okay. afternoon

take it or XX% starting looks bulk $XX base, the out sequencing year-over-year. order So, million like the we so on if consumables, you of grew

relative So, to seems on to the the step in surface, right half performance. first a that direction be

almost in than However that in was expected of came $XX forecast jump a you up still my the light bigger million instrument quarter. with and revenue

at I sequencing my are imply are you revenue. growth quarter seems reducing consumable guidance for for it assumption consumable your while to your in And from clear you standpoint, prepared completely your least that sequencing fourth full on year remarks, the guidance in

right? math my is off, first So,

what we the average a isn’t I similar stacks Second, we on we’ve expectation has XX% we And past growth predictable. least if it at consumable company. even expected? is year be for at history, should your half, in visibility ability to growth seen do when sequencing you your looks And has for What and sequencing as term, look is Illumina more to NovaSeq exactly revenue two longer been to supposed the given overall forecast then, what first changed? the ramping the this think reach why conclusion growth

normalizes Using stacks for bulk orders.

reason that I way. do at the that’s So

to low your that, third we Francis? Or half, and we going take the more to normal? looking you fourth that for levels. performance quarter to through double-digit assume Is new your growth second it quarter guidance, are As look the is seems moderate stacks when than

fee the that’s but It biggest a the thing. in payment seems quarter lot, one And – platform like upside access the upfront was to then, driver more I know you. QIAGEN

a strategy That that Day. GeneReader already component Analyst growth their as You said, June their at talked QIAGEN about of this guidance. XXth indicated in was

understand as something You guidance growth your how company’s a little hard XXth. in days this July to on last included independent for something later. that you presented provided XX go an that could was guidance It’s driver to

So, want you. Thank sure, am make to Sam I not missing I just that anything.

Sam Samad

Doug, questions. the obviously you to so, is thank for Yes, few here. a There parts it

and comment. can also Francis maybe start I’ll So,

regards regard So, what full me in to to to let growth and start my with year QX terms to sequencing I’ll QX, that with means looks then that as try and clarify expectations like well. and the what consumable make way of and for sequencing consumables

necessarily I what for give won’t looks can Although new normal, to comment you on I sense what’s a our but of like QX the expectations.

from So, quarter by the for we some grew XX% for stocking you QX, sequencing for if and normalize activity. activity, was of consumables China of stocking some it normalized the in XX% last

expected. QX the in to actual we the results expectation better you it in So the our if was or and that’s than quarter, if and in fact, that’s QX actually for – expectations compare it

came slightly deal to better itself. normalizing in anything licensing than for related quarter, revenues we revenue by lower expectations in IVD had sequencing consumables So, we that DTC offset were the fact for better revenues, the for the quarter because

Now, for is the fact down at are and full correct so - guidance year, the thing sequencing year. you the we look one if consumables slightly I have on modestly taken for that, QX

year full in were sequencing mid-teens sequencing to low-teens. and be we we initially So, consumable in in the now consumable expectation for terms the growth are of the growth expecting

Francis pull-through with And drivers the on driven to on that by regards the some that earlier mostly commented non-High-Throughput reduction instruments. is of

that expecting seeing most regards pull-through we NextSeq full lower MiSeq of to with year. that and the for the with So to guidance drives the that we are lower are regards

the now consumable sequencing growth. QX, And be terms in to of in QX we are with regards expecting finally to high-teens

benchtop So, have get modest back phenomenon. consumables. growth we are sequencing highest we do in the the for desktop I terms full acknowledging in mentioned, to in our the and reduction by of terms a quarter of QX outsource consumable Albeit in driven year and we do that that’s as and the sequencing year

Francis deSouza

in then particular, long of QIAGEN a a partnerships of sequencing strategy you And partnership for in part as our we terms been time. strategy and – has core our know,

been XBOX and launched launched then by we the open we it was and number MiSeq of XXXX, on and as in our the companies a we’ve Amoy since of in discussions it the other when and over Berry number platform they a way partnerships clear where number Rock in an IVDs signed build end the of Burning like fact, we with In and systems FDA the and that years. platform China

else from have QIAGEN for to plans a and talking news about been like their We about did not We learned GeneReader put have frankly, them talk to GeneReader we while. everyone did the they out.

So conversations their panels with their them has and been IVD around our portfolio there.

those part and as And market. to building important strategy that and panels our and those same to the an continue our bring be of panels sequencer so do the thing Adaptive, with

help be clinical drive to that platform bring technology And and engine to so, to our is for view can the and platform going really the our us sequencing partnerships market to look sail expand steps. as a our we those

Operator

question… next Your

Sam Samad

can’t add timing I’ll comment in I with to the maybe as our around one guidance QIAGEN, collaborations. did potential of said but we regards, that, guidance, around with points your mean, expected address discussions more we Francis revenue just from have the partnerships And thing and

Operator

Your Dan next from UBS. question Brennan comes from

open. ahead. go Your is line Please

Dan Brennan

XQ. as about taking guiding NovaSeq fourth a Thank doubling to look Great. placements the XQ towards to you I versus still are question know out ask I quarter, you a in questions. we wanted the for

mentioned what you the how towards Q&A towards know, Francis, that occurred confidence and I much kind datapoints the of in Biobank QX. can UK in was wondering So in prepared I number. reaching share just maybe am or incorporated you remarks or

is then I there third possibly know entering that, the about have So of uptake force. to your and today you kind of in customers there mentioned QX upgraded a related

it related what’s introductions? customers most the facilitate these be pricing be possibly of to a of am to you’ve that cell confidence whether needs as ultimately customers I the your question, is to of upgrading there kind and Thanks. rest to done wondering, full pointing So as possibly new the and level upgrade, or anything been you

Francis deSouza

to orthogonal about Sure. There QX. good of vectors us a placements are NovaSeq that lead in number feel

I we the of are back So the will start of the pleased we placements that, look saying year. very with NovaSeq over as course the also by frankly, year, NextSeq over and

strong are entering around NovaSeq momentum with we placements. So QX

we the we much last into We look how put to the a could guidance that of pipeline we’ve slightly still number that flat up that year. meet line of the at drive to of from are have number And opportunity the left potential fact will we sight installed there – we out, third of deals placements if the but be is we then need so us that front only are base, the of Greenfield of to to that the we about year. course journey and have a in to about the get lot over addressing the get in still upgrade begun talked customers number HiSeq is opportunity of that

all vectors to placements. level So, point those NovaSeq comfort of around the our

Operator

comes question Derik Bank De of from next Your from Bruin America.

Your open. go line ahead. is Please

Derik De Bruin

Hello Couple of and good questions. afternoon.

potentially contribute magnitude are out is, of as and given couple can sort one, gets got that like now your you mean, right looking get thinking just I both so could NHS talked and in you there UK a I And confidence know, a of questions, they those uncertainties coming the on on particularly is look Brexit XXXX? and about on? feeling on any you one at be one, what to good wanted follow-up. of could about and us you us some I – all the I’ve of pushed understand going the a NHS the First incremental that And of in then, reason the in sense how to help about in

Francis deSouza

Sure.

about talk I’ll NHS. and go about you the deal specifically. I’ll So, talked with that the start

we’ve believe this really So, them that high in will we coming the the will no ramp year. up happen a year, confidence from in half revenues working next on it we have it with of year. we in first NHS fact happen of And that have the been degree which next

now with what of working looks are shape we curve What the is like. them that

little off bit to point the more XXXX like. and I will high of it while okay, work we what still discussion back the what come confidence is us and a for curve say, so, the so And to will a so, NHS, this that’s take shape you have that kick looks

it because NHS year this at is do we of any all didn’t incremental, revenue Regardless, all.

in side. and working where All part next look we expect you with Us of on on we Us also early through similar year of sequencing team array a the are the the side fully ramp and on All the in the happen play both If of to are we at that

the now. done of so incremental. right are feel has the working fact And good to again, of results the recruited all that of and that they is consent that work on that They go. about I already participants All and have they have ready Us around return

year. we have of kick-off have it they but the So like a go you of I will ready and off. kicks it what as will next go once come Again look is all into to confidence lot that be infrastructure back that incremental to will to we’ll going with

Operator

next comes Wolfe Research. Steve Your question Beuchaw from from

Please go open. is line ahead. Your

Steve Beuchaw

Hi, be it’s Happy to Beuchaw. here. Steve

Francis deSouza

Steve. Hi,

Steve Beuchaw

I ultimately demand to Puneet’s of the that a call theme acceleration address, agree I it’s would the driving with is story. really and think wanted of and elasticity associated of to to elasticity kind Nova central the with earlier critical NovaSeq. it’s but comment try I

would see be and very which a aggregate BaseSpace, in period-to-period, wonder don’t from is to if right? demand not see leverage of the opportunity data that get I Illumina you way and to get able project necessarily new those outside on From might you to of you is flow So through being CMS to the interesting us you generation, see. you be level? It a and evidence are unique sequencers coming in data revenue on BaseSpace but that on at for just sequencing what elasticity end-user growth whether today, seeing you where for hear have

Francis deSouza

out really things That’s we so some imagine, question, uncovered monitor I’ll the we’ve as that Steve. we in look do closely can a far. data get pull customers activity of very the some – our into great what are And you to BaseSpace doing. and at insights

the customers happens that is things pretty we NovaSeq. closely of a what at transition One look with to

And so, a from at High-Throughput-to-High-Throughput look we conversion. it

is consumable in as a to view to the NextSeq and per their customers perspective overall customer who a from NextSeq high adds we or drop you see they lower are because or a look customer, when to not. So what leverage happens spend, who a peak okay, able NovaSeq primarily at cost say NovaSeq they ex to NovaSeq, know

what will they And we or a of that growth upgrade to that their their business. customers NovaSeq is are – are in an finding those consumable NovaSeq right? That will add scenarios believe in because they in both you actually and expansion having spend, see

– you so And give some will color. anecdotal I

the customer the primarily into way customer. we segments get for sequencing-intensive primarily they So business. oncology example, example. That look add really their was was in a as incremental of NovaSeq more some NextSeq that for the purchase to And had a NIPT

helps the case oncology space. for so, into put And NovaSeq their business to the together entry

primarily it And NextSeq, NovaSeq. to continuing the so its can on for expanding on that but had its of that’s customer an a example sequence a business economics is on business NIPT based get

utilization. kinds are NovaSeq look also driving that the We the at applications of

– So we look X. than platform on generating genomes is and very customers over are volume Last as hard to platform we the at and data our where crossed a is expect more of now we doing data any they to certainly had. quarter other HiSeq be NovaSeq path It’s NovaSeq high. we

in those expect we We NovaSeq. exomes to expect and applications be we as what genomes, expect that finding biggest we exactly are again that are would is

cost-effectively. machine again where more cases most big of finding And that’s not the to sort are using NovaSeq as run other are We to on customers applications a the genomes.

in those seeing can and around qualitative BaseSpace. again customers so, that how we I datapoints the at what some and share are using look of mix we with And you are the

Operator

Jack next is Meehan Barclays. Your question from

Please Your line is go open. ahead.

Jack Meehan

afternoon. had Good just you. two-parter. Thank a I

POPSEQ things First, customers hear by volume be one of to the from price. big the we is that is going the dictated

just is the when elasticity? you thoughts flow if on any right on have price cell the innovation you was curios pull to lever I time and think So,

just question, projects get big you some of we that depending curious, some you have guidance that January, as more time? thinking obviously, of these as about projects these big to at of level on a And philosophy are then, early have are am guiding the sitting been how visibility of here, around we I delayed.

Francis deSouza

another It’s question. great

that So, over we of we world are these as and of that actively sequencing the pricepoints. initiatives around them we lower if sense with XX more fact could some will quickly you talk population now the access they engaged to customers, move are with our start the right in

price. the is to on elasticity opportunities And definitely so move could those there some of related the pace some

and we we close have we where do what Gel engage our we’ll for term do flow What project do to with good to to the to done able as discussions on for sight instruments line into is, of initiative we’ve before, are example into a and are at roadmap looking term of going price around of to over get project an own forward able and technology and we getting the go, cells the that customers expect and our based we go. of we ready

and kinds discussions accelerated getting can engage once line. so, we over gets to initiative done, those of getting a And the closer to

we talked have. sure their to in go, roadmap needs let has get to can I into to initiative visibility make to that not that, the get about right, those won’t ready been a pricing feel we on engage match done. And discussions So it on far, of that to the we an the based is any gating can factor as pricing initiatives the we that we

as their also the patient, overall, sequencing. sample with price engage of is price that price that them, just so more than their much We per know per we

And with so, reference we help the architectures.

implemented a where partners. examples have in way we with have of been an set We end-to-end

customers helping so down look about And like. what think end-to-end take per could the cost and help system take patient by out our of them the friction overall we the flow and per sample

Sam Samad

Jack, philosophy. last mean, is around visibility not I can some initiatives high a quarter, maybe perfect to we talked uncertainty where the in – them. guidance there these them are of cautious taking about of And because don’t I’d comment, time. genomics more we degree say a on have an a the We it’s perfect and as to I approach population

process of start that said them case-by-case to certainty at and Having that to Those to this, high have samples. look those where degree will will understand we they will individually try around start recruited and we are have visibility that - different with that to have have specific those timelines those and the have patients, milestones governments we and as that well. discussions deliverables obviously very actually

insights are. ones, we we what good at good they’ve We All look know we of on recruited specific they have for as Us. where that. We visibility So, the know have and

XXXX. degree that and think curve a start high commissioning, of of there The certainty is how what So degree have high I in looks it’s will question that that that happening, that a as to alluded happening we Francis a certainty NHS of much earlier. like will start

be in general too flux, the about others early UK and you the that’s is part Biobank there well. Obviously, our that ones philosophy. as But that will build tell like XXXX, that but to

Francis deSouza

number so everybody UK ones And three mean, we of are those I knows that so ones are the months. been the those personally big a And to just I’ve last times involved. now I

how have playing we out. good like feel I those into visibility So, are

Sam Samad

that one sorry. last one Yes. thing Jack on And

and ones specific we ones will not the be telling which in that. you and We also on which will are transparent transparent guidance are on be included and so

Operator

from open. Ji Your comes question ahead. go Sung is Please next from line Your BTIG, Nam

Sung Ji Nam

Hi, thanks question. the for taking

was competitive funding are Thank guess, Just I that you China there if on issues. I seeing, you another comment competitive understanding on greater wondering dynamics some question could there you. was the headwinds. what

Francis deSouza

by saying It’s I’ll not the Sure. change reaching we that in a environment. are start China. competitive competitive a overall, in dynamic

out and the We driven dynamics something monitor The are very seeing and there clinical closely. is growth market are that by we it’s NIPT. playing oncology we maintaining our in China share definitely is in

that And that’s growth continues to the strong double-digit be and case.

are in it. And participating so, we

our even The The maybe share. down. are there side the other the slowed players anything better market if in little we doing in participating holding of market it. research are And has than bit

growth say, growth we we, industry and an I saw market saw in we as in that XXXX. So

show funding XXXX as that we, well a the seeing in and last market. – We down in definitely research we so, are that market are the and are year research numerous from other side saw deceleration we as a seeing are overall the of players this There market in that space has in in slowdown research the overall arena gone in datapoints growth year. seeing that

happening players So, across that’s the market. in

Operator

Your Quirk Piper go Bill from Please Jaffray, comes question line is next open. Your from ahead.

Bill Quirk

thanks Great, everyone. end here. from afternoon my question good and part Two

NovaSeq respect been systems placements, deployed? off, to UK for the first Biobank has project has all the So with the

timing In comments, And then, highlighted the of words, the relative think secondly, can you rugged lot we catalysts, some Francis, things them? test number, of some you the like of we about if obviously prepared for outstanding talked at reimbursement had the about that for some for your we terms guidelines a help other catalyst us through FDA of funding of importance of end we’ve moving think a about today or have which all approval endorsements really clinical NIPT, have them in popgen.

us about just relative you this? think help could of Thanks. So, magnitude the

Francis deSouza

Sure.

with start me Let that had. UK the Biobank question you

ramped are up the the and So, that UK are the have they labs doing Biobank sequencing. for certainly sequencing

course over the augment to Now, the they But off. they certainly may choose that have possibility. project they are a of fleet that’s the and

to and got get are going. get in need to started they sequencing what full have they force They

you most QX end pointed So, course it’s again talk bit parts and next the over as number a The moving clinical let market of there the and out, play the going clinical out in QX are at year. market, what's about to little you’ve of there me important. that question a happened was and and of to big asked,

And of I’ll a segment start in a little bit story.

with the going that to decisions Europe. So are drivers In coming out are of NIPT. NIPT, start of biggest the I’ll be national growth

is true for actually that’s doing reimburse is and and doing a European France in story Germany, to and is for doing what that’s So, doing, UK seeing adding Denmark the example, Netherlands is and Japan. high-risk

averages. hold when we to And reimbursement in U.S., the be last risk cover outs going it’s around you two see the the need but to average

say, to continuing reimbursement are getting around big story I’d NIPT, is and in we So seeing that. expand the

making accelerating to in the the growth probably terms on rate and of are that’s fire going We in NIPT. the be fuel progress biggest the

in to jump terms get oncology. In of genetic I’ll good progress reimbursement. disease we’ve I’ll disease, – to very of then terms genetic and In made

the access in genome So event lives now in exome the have U.S., there and are whole has over sequencing a covered million or child to disease. the genetic a - whole that that XXX

is bottleneck is look in if indication that have just and the bottleneck although have months, the XXXX The there ordered. we tests back not the a there U.S. XXX,XXX over utilization so, reimbursement. place, children last the condition here are reimbursement there in over The and XX

to so disease be biggest U.S., the the big in genetic going And utilization. market is the the and around there in driver opportunity is near-term the

And results educating test order they when interpret that the the the to physicians get able around sure when they are to the making test.

clinical teams the And and like customers so, genetic in Hospital are our affairs, lot of great and a that’s through disease. around doing work awareness through medical affairs partners that that’s San Rady's we of Children's Diego sort driving

seeing In very growth. strong oncology, are we

are already, to are continue build. seeing seeing we reimbursements We

of things panels number IVD growth so, availability hospitals. seeing to of product accessible community makes an are One now there acceleration is are that rate. the will there, drive proliferates of the that We these that tests and further

big are All of centers. academic action the growth it’s seeing there, driven though cancer even happening the we in oncology, in

labs. So the sophisticated

acceleration catalyze will And market. actually so, IVD further of of an that availability an

access emerge patients therapies. get continued NGS then, therapies the of And precision to therapy as more development market, pulls the need to for those the oncology testing really in for it

So oncology. in those are some of the big drivers

Operator

Please go Your ISI, line question comes ahead. from Your Evercore next from Vijaykumar is open.

Vijaykumar

for the Maybe Thanks housekeeping XD, at collaboration Q, underlying in margins taking of give a start margins what and payments? question with the looking I guess I’ll I Sam, guys. for ones. the quick the one. Hey can had you sense two my

Sam Samad

and for of all driven had all the XXX% better strong very revenue, the the it’s to revenue And deals. call. and the licensing Yes. essentially, your really the the to a some Vijay, driver margins. margin welcome than question actually because margins. It’s We expected but are thanks quarter key those was margins question that, for IVD at in from

Operator

line open. from go Mark Genuity, is from is Canaccord Please Your Your ahead. next question Massaro

Mark Massaro

And you you an think here to QX, is will additional then, give to partner? broadly Francis, I you talk what that QIAGEN? revenue why additional can platform think was in more sense from Thank I of guess, us on to fee And of recognized question. ideal related driving types a sequencing? you’ve guess, for kits Hey. the the QIAGEN of incremental access you just the how much be

Sam Samad

I Yes. that of and first for take thank will you the Mark portion question. the

access which we by reflects that revenue down QIAGEN, We driven we reflects – got other haven’t fees but also well. and was some as we million approximately that this the broken partnership indicated, revenue $XX from recognize as deal

just access it’s for the So, fees. entirely not

Francis deSouza

partners what you second Yes, and a them how which we question partner part partners our that and and And did that that we why menu for what us with take clinical domains. them good do choose and on the why expand access that then, will are an choose of choose. looking I’ll give ecosystem we the of the to we makes additional and is is sequencers choose do

where their And so, strong, are if they you look at what has QIAGEN today in right. portfolio and

they any market don’t domains, small they cancer panels cancer ourselves And a set small So, clinical of really. also in panels strength and to have we other take right. have

a other So infectious they the to number business to have they and clinical where market. already take commercial have for disease example products domains capabilities of of a

of us and to and into have cancers. for they line relationship also in at That’s exciting if our areas how in us us. other Adaptive, that’s in look so, in exciting like, this at for products monitoring and expand the clinical got gives for point domains. of And terrific for also MRD example, starting blood Similarly, could immunology set you relationship sight a

unique access take us give to they can so customers. menu And to our that we

what that’s should looking so, be you And for.

Amoy, Our China us gave to Berry, to things. other two access They example, access for Annoroad, of partnerships set in tests. a us gave

access So that and us to in gave sequencer case, they geographic menu distribution. in our also

are long-term business. select business way sequencing is different been we fundamentally strategic the are choose that areas, part all This value It maximize a to end-to-end platform solutions the And of to always capabilities opinion as looking the fundamentally, relevant some we is while our some domains of for. are these part to This has for plan. best believe sign our partnerships. so, those is our we we of market ourselves play and in across we take in

set To view us reach. that ourselves find access and then best commercial access partners as give of both a platform menu to to the and

Operator

Derik is line of from from is open. America, question Bruin ahead. De Please last Your go Bank Your

Derik De Bruin

for Thanks taking Great. again. me

what Jack have sure question I wasn’t I but the So, question to I the slowing that seeing sort desktop could asked that QX? sort of quite situation about a and in sort guide wanted underlying wanted I and and is, that elasticity of just how follow-up which the the of in why resolving essentially again that you to of were actually you go – mid clarify thought see of the and on the through cost you

Francis deSouza

have started quarter call. call we to that data. we And on QX out so, in additional the now of Yes,

of that top-end customers are bigger customers to And similarly, the systems so, to the One NovaSeq. what and transition to customers up volume we some that is that played two at MiSeq transitions out. playing started we are NextSeq seeing out is playing high out moved we purchase NovaSeq seeing migrate and platform had

customers before, they one to we’ve so, out typically bigger said And more the trend and move sequencing. whereas as systems, moving out full to as seen this up play customers I because playing to system expect bigger do

and incident. pull-through per while some near-term expect spend to their of take pull-through that volume growing pressure we business, puts instruments the sample pressure increase of so, grow and consumable sort for time And to on over the

to is, that that the seeing trend people market. DX are second embracing NextSeq The the brought we we

as saw DXs. purchase that both to are the And NextSeq base customers so, base as we NextSeq well on the MiSeq starting

takes year and in the drove as Now, trend those pull-through that quarter. time total Again, down the box NextSeq that’s them clinical per XX% instrument really XX% as business for up, from XXXX them validate a the to we and in in pull-through, the our to positive XXXX. percentage boxes of ramp DX shipments a little long-term, a believe so and for move last NextSeq

on pressure clinical NextSeq really a ramp it’s sign they again, those growth. put perspective. good progress a But for near-term, from up. long-term new the boxes In pull-through until So per DX good

Sam Samad

to add range. NextSeq Maybe at thing below MiSeq I pull-through would we would the in said the of would both reflects low end timeframe everything expect terms be to only when continue pull-through range the that, as is QX the assumption Francis the the that this for, happening of be to and

included So, are in current be what’s very just our this to QX and in guidance. expecting clear, we that’s

Operator

to the would I now Jacquie Thank over you. call like Ross. to back turn

Jacquie Ross

Christina. Thank you,

we section us As a in to today. will for Thank look reminder, a webcast a update, the concludes our our call you replay available call of following This be joining the close of and Investors next this forward the of website, our XXXX. as

Illumina (ILMN) 25 Oct 192019 Q3 Earnings call transcript